Human serum α1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 6, 1996, Pages 1491-1497

  Bilello, J A ^a   Bilello, P A ^a   Stellrecht, K ^a   Leonard, J ^b   Norbeck, D W ^b   Kempf, D J ^b   Robins, T ^b   Drusano, G L ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 80987; ANTIVIRUS AGENT; OROSOMUCOID;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEINASE INHIBITION; VIRUS INHIBITION;

EID: 0029891663     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.6.1491     Document Type: Article

References (34)

1. Bilello, J. A. Unpublished data.
2. 1a Bilello, J. A., G. Bauer, M. N. Dudley, G. A. Cole, and G. L. Drusano. 1994. The effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob. Agents Chemother. 38:1386-1391.
3. Bilello, J. A., P. A. Bilello, J. J. Kort, M. N. Dudley, J. Leonard, and G. L. Drusano. 1995. Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro. Antimicrob. Agents Chemother. 39:2523-2527.
4. 1-acid glycoprotein. J. Infect. Dis. 171:546-551.
5. D'Argenio, D. Z. 1990. ADAPT II: a program package for simulation, identification and optimal experimental design. Users manual. Biomedical Simulations Resource, University of Southern California.
6. Debouck, C., G. J. Gorniak, J. E. Strickler, T. D. Meek, B. W. Metcalf, and M. Rosenberg. 1987. Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc. Natl. Acad. Sci. USA 84:8903-8906.
7. Dennissen, J., and S. Granneman (Abbott Laboratories). Personal communication
8. Dudley, M. N., J. Blaser, D. Gilbert, and S. H. Zinner. 1990 Significance of "extravascular" protein binding for antimicrobial pharmacodynamics in an in vitro capillary model of infection. Antimicrob. Agents Chemother. 34:98-101.
9. 2 symmetric inhibitor complexed to HIV-1 protease. Science 249:527-533.
10. Gottlinger, H. G., J. G. Sodroski, and W. A. Haseltine. 1989 Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl Acad Sci USA 86:5781-5785.
11. Holodniy, M., D. A. Katzenstein, S. Sengupta, A. M. Wang, C. Casipit, D. H. Schwartz, M. Konrad, E. Groves, and T. C. Merrigan. 1991. Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J. Infect Dis 163:862-866.
12. Huff, J. R. 1991. HIV protease: a novel chemotherapeutic target for AIDS. J. Med. Chem. 34:2305-2314.
13. Kageyama, S., B. D. Anderson, B. L. Hoesterey, H. Hayashi, Y. Kiso, K. P. Flora, and H. Mitsuya. 1994. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins Antimicrob. Agents Chemother. 38:1107-1111
14. Kempf, D. J., K. C. Marsh, L. C. Fino, P. Bryant, A. Craig-Kennard, H. L. Sham, C. Zhao, S. Vasadanova, W. E. Kohlbrenner, N. E. Wideburg, A. Saldivar, B. E. Green, T. Herrin, and D. W. Norbeck. 1994 Design of orally bioavailable, symmetry-based inhibitors of HIV protease. Bioorg. Med. Chem. 2:847-848.
15. 2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 35:2209-2214.
16. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.
17. Kort, J. J., J. A. Bilello, G. Bauer, and G. L. Drusano. 1993. Preclinical evaluation of antiviral activity and toxicity of Abbott (A)77003, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother. 37:115-119.
18. Kort, J. J. Alterations in membrane cation transport in CD4+ T cells infected with human immunodeficiency virus type 1. Submitted for publication.
19. Krausslich, H. G., and E. Wimmer. 1988. Viral proteinases. Annu. Rev. Biochem. 57:701-754.
20. Kremer, J. M., J. Wilting, and L. H. Janssen. 1988. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev. 40:1-17.
21. Loeb, D. D., C. A. I. Hutchinson, M. H. Edgell, W. G. Farmerie, and R. Swanstrom. 1989. Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases J. Virol. 63:111-121.
22. Louis, J. M., E. M. Wondrak, T. D. Copeland, C. A. D. Smith, P. T. Mora, and S. Oroszlan. 1989. Chemical synthesis and expression of the HIV-1 protease gene in E. coli. Biochem. Biophys. Res. Commun. 159:87-94
23. Miller, M., B. K. Sathyanarayana, M. V. Toth, G. R. Marshall, L. Clawson, L. Selk, J. Schneider, S. B. H. Kent, and A. Wlodawer. 1989. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science 246:1149-1152.
24. Mulder, J., N. McKinney, C. Christopherson, J. Sninsky, L. Greenfield, and S. Kwok. 1994 Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J. Clin. Microbiol. 32:292-300.
25. Navia, M. A., P. M. D. Fitzgerald, B. M. McKeever, C.-T. Leu, J. C. Heimbach, W. K. Herber, I. S. Sigal, P. L. Darke, and J. P. Springer. 1989. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature (London) 337:615-620.
26. Oie, S., M. A. Jacobson, and D. I. Abrams. 1993. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with Zidovudine (ZDV) J. Acquired Immune Defic. Syndr. 5:531-533.
27. Ou, C.-Y., S. Kwok, S. W. Mitchell, D. H. Mack, J. J. Sninsky, J. W. Krebs, P. Feorino, D. Warfield, and G. Schochetman. 1988. DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science 238:295-297.
28. Redington, J., S. C. Ebert, and W. A. Craig. 1991. Role of antimicrobial pharmacokinetics and pharmacodynamics in surgical prophylaxis. Rev. Infect. Dis. Suppl. 10:5790-799.
29. 2 symmetry-based human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 39:1559-1564.
30. Robins, T., and J. Plattner. 1993. HIV protease inhibitors: their anti-HIV activity and potential role in treatment. J. Acquired Immune Defic. Syndr. 6:162-170.
31. Siegler, E., A. Schaefer, and J. A. Bilello. 1982. Interferon-induced alterations in membrane functions and the growth of Daudi lymphoma and Friend leukemia cells. Biosci. Rep. 2:605-608.
32. Wang, A. K. L., and J. C. Hsia. 1983. In vivo binding of propranolol and progesterone to native and desialylated human orosomucoid Can J. Biochem. Cell Biol. 61:1114-1116.
33. Wlodawer, A., and J. W. Erickson. 1993. Structure-based inhibitors of the HIV-1 protease. Annu. Rev Biochem. 62:543-585
34. Zimmerman, T. P., W. B. Mahoney, and K. L. Prus. 1987. 3′-Azido-3′-deoxythymidine an unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J. Biol. Chem. 262:5748-5754.